The EDD protein, also known as E3 ubiquitin-protein ligase UBR5, is a multifunctional enzyme involved in the regulation of various cellular processes, including protein degradation, DNA repair, and signal transduction pathways. As an E3 ubiquitin ligase, EDD plays a crucial role in ubiquitin-mediated proteolysis by catalyzing the transfer of ubiquitin molecules onto target proteins destined for degradation by the proteasome. EDD recognizes specific protein substrates through its substrate-binding domains and facilitates the conjugation of ubiquitin to lysine residues on these substrates, marking them for proteasomal degradation. Additionally, EDD has been implicated in the regulation of DNA damage response pathways, where it participates in the repair of DNA lesions through interactions with key DNA repair proteins. Moreover, EDD has been shown to modulate the activity of various signaling pathways, including those involved in cell cycle progression, apoptosis, and transcriptional regulation, highlighting its diverse functional roles in cellular physiology.
Activation of EDD involves complex regulatory mechanisms that govern its enzymatic activity and substrate specificity. One of the primary mechanisms of EDD activation involves post-translational modifications, such as phosphorylation, which can regulate its catalytic activity and substrate binding affinity. Phosphorylation events mediated by specific kinases can either activate or inhibit EDD function, depending on the context of cellular signaling pathways and physiological conditions. Furthermore, EDD activity is tightly regulated through protein-protein interactions with cofactors and regulatory proteins, which influence its subcellular localization, substrate recognition, and catalytic efficiency. These interactions may allosterically activate EDD or facilitate its recruitment to specific cellular compartments or protein complexes, thereby modulating its substrate specificity and biological functions. Understanding the intricate mechanisms underlying EDD activation provides valuable insights into its role in cellular physiology and its potential implications for human health and disease.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib enhances EDD activity by inhibiting the proteasome, preventing the degradation of EDD protein. This leads to increased levels of active EDD, facilitating its functional activity in cellular processes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132, a proteasome inhibitor, similarly prevents EDD degradation, resulting in elevated levels of functional EDD. This chemical supports enhanced EDD activity by blocking its targeted proteasomal degradation pathway. | ||||||
Calpeptin | 117591-20-5 | sc-202516 sc-202516A | 10 mg 50 mg | $119.00 $447.00 | 28 | |
Calpeptin enhances EDD function by inhibiting calpain, a calcium-dependent protease. Inhibition of calpain prevents EDD degradation, leading to increased functional activity and participation in specific cellular processes. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 activates EDD by inhibiting NF-κB signaling. Suppression of NF-κB prevents its negative regulation on EDD expression, resulting in increased functional activity of EDD in cellular processes. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $107.00 $376.00 $2147.00 | 3 | |
NDGA enhances EDD activity by inhibiting lipoxygenases, influencing arachidonic acid metabolism. This alteration in lipid signaling indirectly activates EDD, contributing to its increased functional activity. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485 activates EDD by inhibiting histone deacetylases (HDACs). HDAC inhibition leads to acetylation of specific histones, promoting EDD expression and functional activity in cellular processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine enhances EDD function by inhibiting cyclin-dependent kinases (CDKs). Inhibition of CDKs disrupts cell cycle regulation and indirectly activates EDD, facilitating its increased functional activity in specific cellular processes. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin activates EDD through increased intracellular calcium levels. Elevated calcium stimulates EDD phosphorylation and enhances its functional activity in specific signaling events and cellular processes. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin enhances EDD activity by activating adenylyl cyclase, leading to increased cAMP levels. Elevated cAMP levels influence EDD activation, contributing to its enhanced functional activity in cellular processes. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 enhances EDD activity by inhibiting NEDD8-activating enzyme (NAE), preventing EDD degradation through the neddylation pathway. This inhibition leads to increased levels of active EDD, promoting its functional activity. | ||||||